secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0000950170-23-009487
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics Q4 net loss $27M, cash $71M; patent litigation progress, PRISM4 discontinued
--------------------------------------------------------------------------------

- Net loss Q4 $27.0M vs $19.1M in Q4 2021; FY2022 net loss $114.6M vs $58.2M in prior year.
- Cash and equivalents $71.0M at Dec 31, 2022; estimated $43.3M at Feb 28, 2023; cash runway extended into 2025.
- Discontinued PRISM4 Phase 3 trial for CP101 in recurrent C. difficile; database locked, no treatment-related SAEs.
- Court adopted Finch's claim constructions for 7/8 terms in patent case vs Ferring/Rebiotix; jury trial set May 2024.
- Repaid $16.2M debt to Hercules, subleased Hood Park facility, and launched Strain Bank for licensing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017023009487/0000950170-23-009487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017023009487/fnch-20230323.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer